Liothyronine Sodium
NDC Package 16590-303-30

11-digit billing NDC: 16590030330

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Liothyronine Sodium is iNDICATIONS AND USAGEThyroid hormone drugs are indicated:As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Marketed by Stat Rx Usa, this product is identified by NDC 16590-303 and is authorized under FDA application ANDA090097.

Identification & Billing

NDC Package Code
16590-303-30
Package Description
30 TABLET in 1 BOTTLE
Product Code
11-Digit Billing Format
16590030330
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Liothyronine Sodium
Dosage Form
-
Usage Information
INDICATIONS AND USAGEThyroid hormone drugs are indicated:As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef.

Regulatory & Marketing

Labeler Name
Stat Rx Usa
FDA Application #
ANDA090097
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
03-20-2009
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 16590-303-30 identifies a specific commercial package of 30 tablet in 1 bottle of Liothyronine Sodium, labeled by Stat Rx Usa. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Stat Rx Usa on March 20, 2009. The current certification is valid through December 31, 2017.

How is this Stat Rx Usa product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 16590030330. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
16590-303-30
11-Digit CMS (5-4-2)
16590-0303-30

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.